Erratum: Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study (The Lancet (2014) 383(9932) (1889–1898) (S0140673614606140) (10.1016/S0140-6736(14)60614-0));Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: A randomised, multicentre study

The Lancet

Volumn 383, Issue 9932, 2014, Pages 1889-1898

  Giles, Thomas D ^a   Weber, Michael A ^b   Basile, Jan ^c   Gradman, Alan H ^d   Bharucha, David B ^e   Chen, Wei ^e   Pattathil, Manoj ^e  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY Downstate Medical Center   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEBIVOLOL; PLACEBO; VALSARTAN;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE; YOUNG ADULT;

EID: 84901776037     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31675-0     Document Type: Erratum

References (21)

1. Wald DS, Law M, Morris J.K., Bestwick JP, Wald NJ Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300.
2. Chobanian AV, Bakris GL, Black H.R., et al, and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
3. Mancia G, Fagard R, Narkiewicz K., et al 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
4. Salahuddin A, Mushtaq M, Materson BJ Combination therapy for hypertension 2013: an update. J Am Soc Hypertens 2013; 7: 401-07.
5. Bangalore S, Kamalakkannan G, Parkar S., Messerli FH Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-19.
6. Sherrill B, Halpern M, Khan S., Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011; 13: 898-909.
7. Imaizumi S, Miura S, Yahiro E., Uehara Y, Komuro I, Saku K. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2013; 19: 3002-08.
8. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011; 33: 1150-61.
9. 1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59: 16-21.
10. Vanhoutte PM, Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013; 13: 265-73.
11. Hussein O, Shneider J, Rosenblat M., Aviram M. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002; 40: 28-34.
12. Ogawa S, Mori T, Nako K., Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006; 47: 699-705.
13. ICH Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Principles for Clinical Evaluation of New Antihypertensive Drugs. 2000. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm073147.pdf (accessed Feb 1, 2014).
14. US Food and Drug Administration. Ttile 21. Code of Federal Regulators. Section 310.545. Subchapter D: Drugs for Human Use, Part 300, Subpart B-Combination Drugs. Washington, DC: US Department of Health and Human Services, 2013.
15. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-02.
16. Gradman AH, Basile JN, Carter B.L., et al Combination therapy in hypertension. J Am Soc Hypertens 2010; 4: 90-98.
17. Makani H, Bangalore S, Supariwala A., Romero J, Argulian E, Messerli FH Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J 2013; published online Aug 21. DOI:10.1093/eurheartj/eht333.
18. Markham A, Goa KL Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
19. Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension. High Blood Press Cardiovasc Prev 2005; 12: 27-35.
20. Kountz DS. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Postgrad Med 2009; 121: 14-24.
21. Weir MR, Levy D, Crikelair N., Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20: 807-15.